文献速递食管与纵隔外科

新辅助治疗反应对局部晚期食管腺癌的预后价值

Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-12-15

基于美国国家癌症数据库2006-2016年2870例接受新辅助化疗或放化疗后R0切除的局部晚期食管腺癌患者,病理反应完整性与总生存呈剂量反应关联,完全反应HR 0.55。新辅助放化疗较单纯化疗提高原发灶和淋巴结病理反应率,但仅淋巴结反应与生存改善独立相关。

要点

  • 病理反应完整性越高,生存越好,完全反应HR 0.55。
  • 新辅助放化疗较化疗提高原发灶和淋巴结反应率。
  • 淋巴结反应而非原发灶反应与生存改善相关。

核心结论

  • 对新辅助治疗的病理淋巴结反应而非原发肿瘤反应与改善的生存相关。
  • 数据提示需优化新辅助策略以获得更完整的淋巴结反应率,并考虑对食管切除术后残留淋巴结病变患者行更积极的辅助治疗。

研究设计与样本

  • 纳入美国国家癌症数据库2006-2016年年龄18-80岁、临床分期局部晚期(cT2-4或cN+)的食管腺癌患者。
  • 患者均在新辅助化疗或放化疗后接受R0食管切除术。
  • 共纳入2870例患者,构建多变量Cox比例风险回归模型评估治疗反应与生存的关联。

主要发现

  • 2870例患者中,反应完整性与总生存呈显著剂量反应关联:无反应为参照,部分反应HR 0.81(95%CI 0.72-0.91),完全反应HR 0.55(95%CI 0.47-0.65)。
  • 新辅助放化疗较单纯新辅助化疗与更高的病理原发肿瘤反应率相关(33.9% vs 21.3%;P < .001)。
  • 新辅助放化疗较单纯新辅助化疗与更高的病理淋巴结反应率相关(55.9% vs 32.7%;P < .001)。
  • 原发灶和淋巴结反应均与改善的生存相关。
  • 在原发灶有反应但淋巴结无反应的患者中,原发肿瘤反应与死亡风险无关(HR 0.88;95%CI 0.69-1.11);在淋巴结有反应但原发灶无反应的患者中,淋巴结反应的生存获益维持(HR 0.66;95%CI 0.58-0.76)。

临床怎么用

  • 评估新辅助治疗疗效时应重点关注淋巴结病理反应状态。
  • 对食管切除术后残留淋巴结病变的患者,可考虑更积极的辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the association between neoadjuvant chemotherapy and chemoradiation therapy on completeness of pathologic response and to assess the impact of primary tumor versus nodal response on survival after esophagectomy. METHODS: Patients aged 18 to 80 years in the National Cancer Data Base (2006-2016) with clinically staged, locally advanced (cT2-4 or cN+) esophageal adenocarcinoma who underwent an R0 esophagectomy after neoadjuvant chemotherapy or chemoradiation therapy were included. Multivariable Cox proportional hazards regression models were constructed to assess the association between treatment response and survival. RESULTS: Among 2870 patients, there was a significant dose-response association between completeness of response and overall survival: no response (reference), partial response (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.72-0.91), and complete response (HR, 0.55; 95% CI, 0.47-0.65). Compared with neoadjuvant chemotherapy alone, neoadjuvant chemoradiation was associated with higher pathologic primary tumor (33.9% vs 21.3%; P < .001) and pathologic nodal response rates (55.9% vs 32.7%; P < .001). Both a primary and nodal response were associated with improved survival. However, among patients with a primary but no nodal response, primary tumor response was not associated with risk of death (HR, 0.88; 95% CI, 0.69-1.11). In contrast, among patients who had a nodal but no primary response, the survival benefit of a nodal response was maintained (HR, 0.66; 95% CI, 0.58-0.76). CONCLUSIONS: Pathologic nodal (rather than primary tumor) response to neoadjuvant therapy is associated with improved survival. These data suggest a need to optimize neoadjuvant strategies associated with more complete nodal response rates and to consider more aggressive adjuvant treatment for patients with residual nodal disease after esophagectomy.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Groth SS, Burt BM, Farjah F, et al. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018. PMID: 30711279. doi:10.1016/j.jtcvs.2018.11.131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。